{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:01:45Z","timestamp":1790769705485,"version":"4.1.0"},"reference-count":31,"publisher":"American Association for Cancer Research (AACR)","issue":"9","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004376","name":"Terry Fox Research Institute","doi-asserted-by":"publisher","award":["1078"],"award-info":[{"award-number":["1078"]}],"id":[{"id":"10.13039\/501100004376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014823","name":"VGH and UBC Hospital Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014823","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Ampullary adenocarcinoma is rare, and its immune biomarker landscape is incompletely characterized. This article evaluated mismatch repair (MMR), programmed cell death ligand 1 (PD-L1; CD274), and compartment-specific CD3 (CD3E)\/CD8 (CD8A) tumor-infiltrating lymphocytes (TIL) in resected tumors and explored associations with disease-specific survival (DSS). Ninety-nine patients underwent pancreaticoduodenectomy at Vancouver General Hospital (VGH) between 1984 and 2013. Duplicate 0.6-mm tissue microarrays (TMA) were assessed for MMR proteins, PD-L1 combined positive score (CPS), and stromal and intraepithelial CD3 and CD8 counts. DSS was estimated using the Kaplan\u2013Meier method. Exploratory Cox models were adjusted for age, histologic subtype, pathologic tumor (pT) group, pathologic node (pN) status, and adjuvant chemotherapy. There were 44 DSS events. MMR deficiency (dMMR) was present in 37 of 99 (37.4%) tumors. PD-L1 was evaluable in 87 tumors; 57 of 87 (65.5%) tumors had CPS \u22651, and 24 of 87 (27.6%) tumors had CPS \u226510. Intraepithelial CD8+ T cells were present in 23 of 98 (23.5%) tumors. PD-L1 CPS \u22651, PD-L1 CPS \u226510, and MMR status were not associated with DSS by log-rank testing (P = 0.35, P = 0.98, and P = 0.74, respectively). In the pT-adjusted model, intraepithelial CD8 presence was associated with lower disease-specific hazard [hazard ratio (HR), 0.422; 95% confidence interval (CI), 0.144\u20130.994; likelihood-ratio P = 0.048], although the Wald sensitivity test was not significant (P = 0.074). Continuous log-transformed intraepithelial CD8 counts showed a concordant, method-dependent signal. dMMR and PD-L1 expression were common in this historical resected cohort. Intraepithelial CD8 infiltration was associated with DSS, but the borderline and inferential method\u2013dependent estimates require external validation. These prognostic data do not establish benefit from immune checkpoint blockade.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Ampullary cancer is a rare disease in which treatment is extrapolated from other gastrointestinal cancers. In this cohort, immune features varied among tumors with functioning MMR. CD8+ T cells within the tumor epithelium showed an exploratory association with improved DSS, which supports the prospective evaluation of immune stratification, not immediate treatment selection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0302","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:53:57Z","timestamp":1789768437000},"page":"2291-2298","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Compartment-Specific CD8 Infiltration and Disease-Specific Survival in Resected Ampullary Adenocarcinoma"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1332-7881","authenticated-orcid":false,"given":"Steve E.","family":"Kalloger","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rmrcq20","id-type":"ROR","asserted-by":"publisher"}],"name":"University of British Columbia 1 Department of Pathology and Laboratory Medicine, , Vancouver, Canada."},{"name":"2Pancreas Centre BC, Vancouver, Canada."},{"id":[{"id":"https:\/\/ror.org\/03rmrcq20","id-type":"ROR","asserted-by":"publisher"}],"name":"University of British Columbia 3 School of Population and Public Health, , Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5098-5731","authenticated-orcid":false,"given":"Christine","family":"Chow","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rmrcq20","id-type":"ROR","asserted-by":"publisher"}],"name":"University of British Columbia 4 Molecular and Advanced Pathology Core, , Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7779-4967","authenticated-orcid":false,"given":"Dongxia","family":"Gao","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rmrcq20","id-type":"ROR","asserted-by":"publisher"}],"name":"University of British Columbia 4 Molecular and Advanced Pathology Core, , Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5616-1821","authenticated-orcid":false,"given":"Katy","family":"Milne","sequence":"additional","affiliation":[{"name":"5Molecular and Cellular Immunology Core, Deeley Research Centre, Victoria, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6601-8807","authenticated-orcid":false,"given":"James T.","family":"Topham","sequence":"additional","affiliation":[{"name":"2Pancreas Centre BC, Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6861-4189","authenticated-orcid":false,"given":"Joanna M.","family":"Karasinska","sequence":"additional","affiliation":[{"name":"2Pancreas Centre BC, Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4445-5539","authenticated-orcid":false,"given":"Brad H.","family":"Nelson","sequence":"additional","affiliation":[{"name":"5Molecular and Cellular Immunology Core, Deeley Research Centre, Victoria, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7597-6089","authenticated-orcid":false,"given":"Daniel J.","family":"Renouf","sequence":"additional","affiliation":[{"name":"2Pancreas Centre BC, Vancouver, Canada."},{"name":"6Division of Medical Oncology, BC Cancer, Vancouver, Canada."},{"id":[{"id":"https:\/\/ror.org\/03rmrcq20","id-type":"ROR","asserted-by":"publisher"}],"name":"University of British Columbia 7 Department of Medicine, , Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4099-2422","authenticated-orcid":false,"given":"John","family":"Aird","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/040hqpc16","id-type":"ROR","asserted-by":"publisher"}],"name":"Mater Misericordiae University Hospital 8 Dept of Cellular Pathology, , Dublin, Ireland."},{"name":"9Division of Anatomic Pathology, Vancouver General Hospital, Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7341-1308","authenticated-orcid":false,"given":"David F.","family":"Schaeffer","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rmrcq20","id-type":"ROR","asserted-by":"publisher"}],"name":"University of British Columbia 1 Department of Pathology and Laboratory Medicine, , Vancouver, Canada."},{"name":"2Pancreas Centre BC, Vancouver, Canada."},{"name":"9Division of Anatomic Pathology, Vancouver General Hospital, Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"2026093007333998500_bib1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.23736\/S1121-421X.18.02543-6","article-title":"Demographics, tumor characteristics, treatment, and clinical outcomes of patients with ampullary cancer: a Surveillance, Epidemiology, and End Results (SEER) cohort study","volume":"65","author":"Ramai","year":"2019","journal-title":"Minerva Gastroenterol Dietol"},{"key":"2026093007333998500_bib2","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.ejso.2021.02.028","article-title":"A population-based study on incidence, treatment, and survival in ampullary cancer in the Netherlands","volume":"47","author":"de Jong","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"2026093007333998500_bib3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.14694\/EdBook_AM.2014.34.112","article-title":"Ampullary cancer: an overview","volume":"34","author":"Ahn","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026093007333998500_bib4","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.suc.2018.12.001","article-title":"Ampullary cancer","volume":"99","author":"Zheng-Pywell","year":"2019","journal-title":"Surg Clin North Am"},{"key":"2026093007333998500_bib5","doi-asserted-by":"publisher","first-page":"7970","DOI":"10.3748\/wjg.v21.i26.7970","article-title":"Management of ampullary neoplasms: a tailored approach between endoscopy and surgery","volume":"21","author":"Panzeri","year":"2015","journal-title":"World J Gastroenterol"},{"key":"2026093007333998500_bib6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.2012.7352","article-title":"Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial","volume":"308","author":"Neoptolemos","year":"2012","journal-title":"JAMA"},{"key":"2026093007333998500_bib7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1001\/jama.297.3.267","article-title":"Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial","volume":"297","author":"Oettle","year":"2007","journal-title":"JAMA"},{"key":"2026093007333998500_bib8","doi-asserted-by":"publisher","first-page":"753","DOI":"10.6004\/jnccn.2023.0034","article-title":"Ampullary adenocarcinoma, version 1.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Chiorean","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"2026093007333998500_bib9","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ejso.2022.10.001","article-title":"Impact of histopathological type on the prognosis of ampullary carcinoma: a systematic review and meta-analysis","volume":"49","author":"Shin","year":"2023","journal-title":"Eur J Surg Oncol"},{"key":"2026093007333998500_bib10","doi-asserted-by":"publisher","first-page":"12676","DOI":"10.1038\/s41598-019-49179-w","article-title":"The pathohistological subtype strongly predicts survival in patients with ampullary carcinoma","volume":"9","author":"Zimmermann","year":"2019","journal-title":"Sci Rep"},{"key":"2026093007333998500_bib11","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/bjs.11555","article-title":"Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study","volume":"107","author":"Moekotte","year":"2020","journal-title":"Br J Surg"},{"key":"2026093007333998500_bib12","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"2026093007333998500_bib13","doi-asserted-by":"crossref","DOI":"10.31525\/fda1-ucm560040.htm","article-title":"FDA grants accelerated approval to pembrolizumab for first tissue\/site-agnostic indication","author":"US Food and Drug Administration","year":"2017"},{"key":"2026093007333998500_bib14","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026093007333998500_bib15","article-title":"FDA approves pembrolizumab for adults and children with TMB-H solid tumors","author":"US Food and Drug Administration","year":"2020"},{"key":"2026093007333998500_bib16","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1309\/AJCPGDDE8PLLDRCC","article-title":"DNA mismatch repair deficiency in ampullary carcinoma: a morphologic and immunohistochemical study of 54 cases","volume":"133","author":"Agaram","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"2026093007333998500_bib17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12967-018-1444-4","article-title":"Relationship between mismatch repair immunophenotype and long-term survival in patients with resected periampullary adenocarcinoma","volume":"16","author":"Heby","year":"2018","journal-title":"J Transl Med"},{"key":"2026093007333998500_bib18","doi-asserted-by":"publisher","first-page":"4788","DOI":"10.1002\/cncr.33135","article-title":"Frequency and clinicopathologic associations of DNA mismatch repair protein deficiency in ampullary carcinoma: routine testing is indicated","volume":"126","author":"Xue","year":"2020","journal-title":"Cancer"},{"key":"2026093007333998500_bib19","doi-asserted-by":"publisher","first-page":"5772","DOI":"10.3390\/cancers15245772","article-title":"Ampullary adenocarcinoma: a review of the mutational landscape and implications for treatment","volume":"15","author":"Tsagkalidis","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026093007333998500_bib20","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/ijc.30760","article-title":"Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer","volume":"141","author":"Sideras","year":"2017","journal-title":"Int J Cancer"},{"key":"2026093007333998500_bib21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1177\/10668969231177263","article-title":"PD-L1 expression in ampullary adenocarcinoma","volume":"32","author":"Siddiqui","year":"2024","journal-title":"Int J Surg Pathol"},{"key":"2026093007333998500_bib22","doi-asserted-by":"publisher","first-page":"965","DOI":"10.2147\/CMAR.S513961","article-title":"Association of PD-L1 expression with lymph node metastasis and clinical stage in ampulla of Vater cancer: an observational study","volume":"17","author":"Andrianto","year":"2025","journal-title":"Cancer Manag Res"},{"key":"2026093007333998500_bib23","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1136\/jclinpath-2015-203337","article-title":"Immunophenotyping of ampullary carcinomata allows for stratification of treatment specific subgroups","volume":"69","author":"Leo","year":"2016","journal-title":"J Clin Pathol"},{"key":"2026093007333998500_bib24","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1002\/ijc.32945","article-title":"Quantitative, qualitative and spatial analysis of lymphocyte infiltration in periampullary and pancreatic adenocarcinoma","volume":"146","author":"Lundgren","year":"2020","journal-title":"Int J Cancer"},{"key":"2026093007333998500_bib25","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/onco.13821","article-title":"A case of a pathological complete response to neoadjuvant nivolumab plus ipilimumab in periampullary adenocarcinoma","volume":"26","author":"Pothuri","year":"2021","journal-title":"Oncologist"},{"key":"2026093007333998500_bib26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4103\/jcrp.jcrp_9_18","article-title":"Hyperprogressive disease after nivolumab in a patient with microsatellite instability-high ampullary cancer","volume":"6","author":"Lai","year":"2019","journal-title":"J Cancer Res Pract"},{"key":"2026093007333998500_bib27","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM","volume":"17","author":"Edge","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"2026093007333998500_bib28","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"2026093007333998500_bib29","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"2026093007333998500_bib30","doi-asserted-by":"publisher","first-page":"116015","DOI":"10.1016\/j.isci.2026.116015","article-title":"Deciphering the single-cell molecular landscape of ampullary cancer: a rare gastrointestinal malignancy","volume":"29","author":"Cancino-Maldonado","year":"2026","journal-title":"iScience"},{"key":"2026093007333998500_bib31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0302\/3831019\/crc-26-0302.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/9\/2291\/3834626\/crc-26-0302.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/9\/2291\/3834626\/crc-26-0302.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:33:48Z","timestamp":1790768028000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/9\/2291\/788634\/Compartment-Specific-CD8-Infiltration-and-Disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0302","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8745947","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.34031966","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34031957","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34031963","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34031954","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34031960","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}